Has the rate of progression to AIDS changed in recent years?

被引:21
作者
Carre, N
Prins, M
Meyer, L
Brettle, RP
Robertson, JR
McArdle, H
Goldberg, DJ
Zangerle, R
Coutinho, RA
vandenHoek, A
机构
[1] DIV PUBL HLTH & ENVIRONM, MUNICIPAL HLTH SERV, AMSTERDAM, NETHERLANDS
[2] CITY HOSP, INFECT DIS UNIT, EDINBURGH, MIDLOTHIAN, SCOTLAND
[3] EDINBURGH DRUG ADDICT STUDY, MUIRHOUSE MED GRP, EDINBURGH, MIDLOTHIAN, SCOTLAND
[4] UNIV HOSP GENEVA, DIV INFECT DIS, GENEVA, SWITZERLAND
[5] RUCHILL HOSP, SCOTTISH CTR INFECT & ENVIRONM HLTH, GLASGOW, LANARK, SCOTLAND
[6] UNIV INNSBRUCK, AIDS UNIT, A-6020 INNSBRUCK, AUSTRIA
关键词
year of seroconversion; calendar period; AIDS onset; sexual exposure group; injecting drug users; treatments;
D O I
10.1097/00002030-199713000-00010
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objectives: To investigate whether the rate of progression to AIDS has changed over lime by testing an effect of the year of seroconversion on AIDS onset (Centers for Disease Control and Prevention 1987 revised classification), next to an effect of the calendar period of follow-up. Design: French multicentre prospective study of 385 homosexual and heterosexual subjects and 231 subjects from a multicentre study of European injecting drug users (IDU), all with a documented dale of HIV-1 seroconversion. Method: The effect of the year of seroconversion was compared by the log-rank test. Crude and adjusted relative hazard (ARH) were quantified using the Cox model. Calendar period of follow-up was studied separately for sexual exposure group and IDU and treated as a rime-dependent variable in a Cox model. Results: In the 616 study subjects the year of seroconversion was not significantly related re AIDS occurrence (n = 108): the ARH was 0.88 [95% confidence interval (CI), 0.56-1.38] for those who seroconverted in 1988-1989, and 1.17 (95% CI, 0.61-2.25) for those who seroconverted after 1989, compared with those who seroconverted before 1988. In the sexual exposure group, a clear trend rewards less rapid progression to AIDS was observed in subjects followed in 1991-1992 (ARH, 0.49; 95% CI, 0.24-0.99) and after 1992 (ARH, 0.54; 95% CI; 0.24-1.21), compared with those followed before 1991. This favorable trend was not observed in IDU despite a significant decrease over time of Pneumocystis carinii pneumonia as AIDS-defining illness. Conversely to sexual exposure groups, the frequency of antiretroviral treatment (mainly zidovudine) prescription was still low during the most recent calendar periods in IDU when the CD4 co-int threshold of 200 x 10(6)/l was reached. Conclusions: No evidence was found of a change in the rate of progression to AIDS in subjects who seroconverted in recent years. Furthermore, conversely to sexual exposure groups, the lack of favorable trends in IDU users followed in recent years suggest that health-care systems are not always adapted to their lifestyles.
引用
收藏
页码:1611 / 1618
页数:8
相关论文
共 36 条
[1]   INCUBATION PERIOD OF HUMAN-IMMUNODEFICIENCY-VIRUS [J].
ALCABES, P ;
MUNOZ, A ;
VLAHOV, D ;
FRIEDLAND, GH .
EPIDEMIOLOGIC REVIEWS, 1993, 15 (02) :303-318
[2]   INFLUENCE OF NEUROLOGIC MANIFESTATIONS OF PRIMARY HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION ON DISEASE PROGRESSION [J].
BOUFASSA, F ;
BACHMEYER, C ;
CARRE, N ;
DEVEAU, C ;
PERSOZ, A ;
JADAND, C ;
SERENI, D ;
BUCQUET, D ;
ROUZIOUX, C ;
DELLAMONICA, P ;
GALLAIS, H ;
DELFRAISSY, JF ;
LEFRERE, JJ ;
CASSUTO, JP ;
DUPONT, B ;
VITTECOQ, D ;
HERSON, S ;
GASTAUT, JA ;
VILDE, JL ;
KATLAMA, C ;
SOBEL, A ;
DUVAL, J ;
KAZATCHKINE, M ;
LEBRAS, P ;
EVEN, P ;
GUILLEVIN, L ;
MEYER, L ;
DEVEAU, C .
JOURNAL OF INFECTIOUS DISEASES, 1995, 171 (05) :1190-1195
[3]  
Broers Barbara, 1994, Archives of Internal Medicine, V154, P1121, DOI 10.1001/archinte.154.10.1121
[4]   High risk of HIV disease progression after infection through a sexual partner with AIDS [J].
Carre, N ;
Meyer, L ;
Boufassa, F ;
Deveau, C ;
Persoz, A ;
Rouzioux, C ;
Vilde, JL ;
Bary, M ;
Burgard, M ;
Dellamonica, P ;
Durant, J ;
Gallais, H ;
Mars, ME ;
Gallais, J ;
Dormont, J ;
Delfraissy, JF ;
Levy, A ;
Boue, F ;
Beclere, A ;
Lefrere, JJ ;
Lerable, J ;
Joubert, L ;
Cassuto, JP ;
Reboulot, B ;
Quaranta, M ;
Dupont, B ;
Beuzelin, C ;
Fournier, S ;
Vittecoq, D ;
Bolliot, C ;
Pechalat, MT ;
Herson, S ;
Coutellier, A ;
Gastaut, JA ;
Dhiver, C ;
Drogoul, MP ;
Sereni, D ;
Gomez, V ;
Bachmeyer, C ;
Leport, C ;
Colassante, U ;
Katlama, C ;
Brucker, G ;
Sobel, A ;
Duval, J ;
Majerholc, C ;
Deforges, L ;
Kazatchkine, M ;
Vellay, A ;
Buisson, M .
AIDS, 1996, 10 (01) :77-80
[5]  
Centers for Disease Control, 1981, MMWR-MORBID MORTAL W, V30, P305
[6]  
CRAVEN DE, 1990, J ACQ IMMUN DEF SYND, V3, pS45
[7]  
*CTR DIS CONTR, 1987, MMWR-MORBID MORTAL W, V36, P35
[8]  
Darby SC, 1996, LANCET, V347, P1573, DOI 10.1016/S0140-6736(96)91073-9
[9]   First case of new infection with zidovudine-resistant HIV-1 among prospectively studied intravenous drug users and homosexual men in Amsterdam, The Netherlands [J].
deRonde, A ;
Schuurman, R ;
Goudsmit, J ;
vandenHoek, A ;
Boucher, C .
AIDS, 1996, 10 (02) :231-232
[10]   Antiretroviral treatment and progression to AIDS in HIV seroconverters from different risk groups [J].
Dorrucci, M ;
Pezzotti, P ;
Phillips, AN ;
Alliegro, MB ;
Rezza, G ;
Boros, S ;
Lepri, AC ;
Sinicco, A ;
Angarano, G ;
Tarantini, G ;
Salassa, B ;
Castelli, F ;
Pristera, R ;
Gafa, S ;
Colangeli, V ;
Viale, P ;
Barbanera, M ;
Zaccarelli, M ;
Canessa, A ;
Ortona, L ;
Lazzarin, A ;
Tirelli, U ;
Aiuti, F .
AIDS, 1997, 11 (04) :461-467